[Effect of immunosuppression-induced hypogonadism on bone metabolism after heart transplantation]

Area of Science:

• Endocrinology
• Transplantation Medicine
• Bone Metabolism

Background:

• Accelerated bone loss is a known complication following cardiac transplantation (HTx).
• The impact of immunosuppression-induced hypogonadism on bone health post-HTx requires further definition.
• Osteoporosis is a common consequence of hypogonadism in men.

Purpose of the Study:

• To determine the incidence of hypogonadism in male cardiac transplant recipients.
• To investigate the influence of hypogonadism on bone mineral metabolism after HTx.
• To evaluate the efficacy of testosterone replacement therapy in hypogonadal transplant patients.

Main Methods:

• 88 male cardiac transplant recipients were randomized into normogonadal and hypogonadal groups based on hormonal status.
• Bone mineral density (BMD) at the lumbar spine was measured using DEXA at baseline and after 1 and 2 years.
• Hypogonadal patients received testosterone supplementation in addition to standard calcium and vitamin D therapy.

Main Results:

• A significant prevalence of hypogonadism (24%) was observed in male cardiac transplant recipients, independent of age.
• Hypogonadal patients exhibited significantly lower BMD compared to normogonadal patients (p < 0.001).
• Testosterone replacement therapy did not lead to a significant increase in BMD in hypogonadal patients over the 2-year follow-up period.

Conclusions:

• Hypogonadism is highly prevalent (approx. 25%) in male cardiac transplant recipients across all age groups.
• Hypogonadism significantly contributes to bone loss in this patient population.
• Testosterone substitution therapy showed no significant benefit in increasing BMD in hypogonadal cardiac transplant recipients.